Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Audrey Louboutin"'
Autor:
Chrystelle Girardet, Magali Mathieu, François Vallée, Jacques Le-Roux, Fangxian Sun, Laurence Fabien, Corinne Terrier, Celine Ginesty, Bruno Filoche-Romme, Florence Gruss-Leleu, Maysoun Shomali, Monsif Bouaboula, Sylvie Beccari, Pascal Desmazeau, Gilles Lebourg, Tsiala Benard, Victor Certal, Pascale Vicat, Andrew Hebert, Carlos Garcia-Echeverria, Laurent Schio, Youssef El-Ahmad, Gary Mccort, Claire Muller, Maurice Brollo, Mikhail Levit, Luc Bertin, Hong Cheng, Véronique Loyau, Valerie Steier, Fabienne Thompson, Audrey Louboutin, Fabienne Pilorge, Alexey Rak, Frank Halley, Patrick Richepin, Christelle Perrault, Pierre-Yves Abecassis, Michel Tabart, Albane Courjaud
Publikováno v:
Journal of Medicinal Chemistry. 63:512-528
More than 75% of breast cancers are estrogen receptor alpha (ERα) positive (ER+), and resistance to current hormone therapies occurs in one-third of ER+ patients. Tumor resistance is still ERα-dependent, but mutations usually confer constitutive ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb6b8e31876cd3009f301f509589bd98
https://doi.org/10.1021/acs.jmedchem.9b01293
https://doi.org/10.1021/acs.jmedchem.9b01293
Autor:
Cécile Delorme, Angela Virone-Oddos, Bernadette Tric, Audrey Louboutin, Fabienne Thompson, Christoph Lengauer, Loic Vincent, Nadine Michot, Isabelle Vade, Jean Paul Nicolas, Frank Halley, Youssef El-Ahmad, Bruno Filoche-Romme, Hélène Bonnevaux, Andreas Karlsson, Sylvie Monget, Renaud Morales, Victor Certal, Laurent Schio, Gilles Doerflinger, Sébastien Perron, Jean Christophe Carry, Pierre Yves Abecassis
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 22:6381-6384
From a HTS campaign, a new series of pyrimidone anilides exemplified by compound 1 has been identified with good inhibitory activity for the PI3Kβ isoform. The structure of compound 1 in PI3Kγ was solved revealing a binding mode in agreement with t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53a7ad294cd6eed46f1ac36681f76724
https://doi.org/10.1016/j.bmcl.2012.08.072
https://doi.org/10.1016/j.bmcl.2012.08.072
Autor:
Jean Christophe Carry, Youssef El-Ahmad, Bruno Filoche-Romme, Frank Halley, Loic Vincent, Andreas Karlsson, Thomas Bertrand, Christoph Lengauer, Tsiala Benard, Pierre Yves Abecassis, Peter Below, Alexey Rak, Jean Paul Nicolas, Gilles Lebourg, Audrey Louboutin, Victor Certal, Laurent Schio, Cécile Delorme, Nadine Michot, Fabienne Pilorge, Fabienne Chatreaux, Pascale Lejeune, Fabienne Thompson, Angela Virone-Oddos, Isabelle Vade, Hélène Bonnevaux, Jean Pierre Marquette, Odile Angouillant-Boniface
Publikováno v:
Journal of Medicinal Chemistry. 55:4788-4805
Most of the phosphoinositide-3 kinase (PI3K) kinase inhibitors currently in clinical trials for cancer treatment exhibit pan PI3K isoform profiles. Single PI3K isoforms differentially control tumorigenesis, and PI3Kβ has emerged as the isoform invol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7da44cb5e3b90d40fe34a0bb8a89c84d
https://doi.org/10.1021/jm300241b
https://doi.org/10.1021/jm300241b